Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
- Conference Call and Webcast Today, February 6, 2023 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Feb. 6, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 2, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 25, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022 .
View HTML
Toggle Summary Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Fibrosis regression observed in 50% of patients receiving fazirsiran Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in histologic globule burden Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups Results
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 21, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present on January 9, 2023 , at 11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco .
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
- Announcement on January 9, 2023 , with Webcast at 8:30 a.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Dec. 21, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023 , at 8:30 a.m. ET , it will present topline data from the SEQUOIA Phase 2 study evaluating
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 20, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 15, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 9, 2022 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to
View HTML
Toggle Summary Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
- Arrowhead Earns $15 million Milestone from Horizon Therapeutics plc PASADENA, Calif. --(BUSINESS WIRE)--Dec. 8, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
- Conference Call and Webcast Today, November 28, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Nov. 28, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022 . The company is hosting a conference call today,
View HTML